Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.71 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.71 USD
0.00 (0.00%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.71 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Zacks News
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
by Zacks Equity Research
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
by Zacks Equity Research
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
by Zacks Equity Research
OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 33.33% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Entera Bio Ltd. (ENTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In the absence of a marketed product, Entera Bio (ENTX) is expected to provide an update on its pipeline candidates, mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively.
Entera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Entera Bio Ltd. (ENTX) closed the most recent trading day at $0.91, moving +1.11% from the previous trading session.
Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.
Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Entera Bio Ltd. (ENTX) closed at $0.90 in the latest trading session, marking a -1% move from the prior day.
Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.
Entera Bio Ltd. (ENTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.88, marking a +1.87% move from the previous day.
New Strong Buy Stocks for December 29th
by Zacks Equity Research
SPNS, CRS, DHT, DCBO and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on December 29, 2022.
New Strong Buy Stocks for November 21st
by Zacks Equity Research
AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.
Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD Drug
by Zacks Equity Research
The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.
4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why
by Zacks Equity Research
4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down
by Zacks Equity Research
Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.
New Strong Buy Stocks for November 16th
by Zacks Equity Research
ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 8.33% and 8.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 19th
by Zacks Equity Research
ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.
Entera (ENTX) Up on Positive Results From Osteoporosis Drug
by Zacks Equity Research
Entera (ENTX) gains on positive results from a mid-stage study on its osteoporosis candidate at six months.
Entera Bio (ENTX) is Overbought: Is A Drop Coming?
by Zacks Equity Research
Entera Bio (ENTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company.